pharma · Advanced Solid Tumors · Non-Hodgkin's Lymphoma
Liposome Company
Taiwan Liposome Company
Taiwan Liposome Company is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumors, Non-Hodgkin's Lymphoma, Safety Issues, HepatoCellular Carcinoma, Cognitive Function. No
CN HQ
21 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 21
- Programs
- 6
- Drugs
- 7
- Patents
- 0
Ga68-Dolacga Injection
Phase 1 · small molecule · Safety Issues
Ga68-Dolacga Injection for Safety Issues is a Phase 1 program (small_molecule) at Taiwan Liposome Company with 1 ClinicalTrials.gov record(s).
Internal code PTK16081821
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Taiwan Liposome Company
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Safety Issues
- Status
- completed
- Trials
- 1